Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Medical Device

Blue Sail Medical’s New Catheter Receives NMPA Approval for Complex Coronary Lesion Treatment

Fineline Cube May 9, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has received marketing approval from the National...

Company Drug

Abbisko and Allist Pharmaceuticals Initiate Phase II Trial for NSCLC Drug Combination

Fineline Cube May 9, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256) and Allist Pharmaceuticals Co., Ltd have announced the upcoming...

Company R&D

Profluent’s Neural Network Model Designs High-Efficiency CRISPR Gene-Editing System

Fineline Cube May 8, 2024

Biotechnology company Profluent has announced a significant advancement in the field of gene editing with...

Company Drug

Boehringer Ingelheim’s Anti-Sema3A BI 764524 Shows Promise in Diabetic Macular Ischemia Trial

Fineline Cube May 8, 2024

Boehringer Ingelheim (BI) has announced the publication of results from a Phase I/IIa clinical trial...

Company Drug

Pfizer Pauses Dosing in DMD Gene Therapy Trial Following Participant’s Sudden Death

Fineline Cube May 8, 2024

This week, Pfizer Inc. (NYSE: PFE) announced the unfortunate sudden death of a participant in...

Company Deals

Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China

Fineline Cube May 8, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement...

Company Drug

J&J’s Erleada Plus ADT Shows 0% Biochemical Recurrence Rate in High-Risk Prostate Cancer Trial

Fineline Cube May 8, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Phase II clinical trial for...

Company Deals

China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea

Fineline Cube May 8, 2024

China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South...

Company

Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison

Fineline Cube May 8, 2024

Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for...

Company

AstraZeneca Hong Kong Launches ‘HRDetect’ Program to Offer Free Genetic Testing for Cancer Patients

Fineline Cube May 8, 2024

AstraZeneca (AZ, NASDAQ: AZN) Hong Kong has announced a partnership with Inocras Hong Kong Ltd...

Company Deals

Siemens Healthineers AG Forges Expanded Partnership with Xi’an Daixing Hospital

Fineline Cube May 8, 2024

Germany’s Siemens Healthineers AG (ETR: SHL) has entered into an eight-year value partnership with Xi’an...

Company Drug

Everest Medicines’ Velsipity for UC Receives First Asian Approval in Macau

Fineline Cube May 8, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the regulatory authority in...

Company Drug

Wanbangde Pharmaceutical’s Huperzine A Earns FDA Rare Pediatric Disease Designation for HIE Treatment

Fineline Cube May 8, 2024

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced that its subsidiary, Wanbangde...

Company Medical Device

Andon Health’s Triplex Virus Test Kit Receives US FDA Emergency Use Authorization

Fineline Cube May 8, 2024

Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced...

Company Deals

Citi Pharma Ltd and Hangzhou Newsea Technology Form JV to Boost API Production

Fineline Cube May 8, 2024

Pakistan-based pharmaceutical company Citi Pharma Ltd is entering into a joint venture (JV) agreement with...

Company Medical Device

Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval

Fineline Cube May 8, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal...

Company Policy / Regulatory

Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences

Fineline Cube May 8, 2024

This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...

Company Drug

LEO Pharma’s Enstilar Outperforms Daivobet in Phase III Psoriasis Trial in China

Fineline Cube May 8, 2024

Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar...

Company Deals

Ono Pharmaceutical Secures Deal to Acquire Deciphera Pharmaceuticals for USD 2.4 Billion

Fineline Cube May 7, 2024

Japan-based Ono Pharmaceutical Co., Ltd (TYO: 4528) has announced that it has reached an agreement...

Company Drug

Mabwell Bioscience’s 9MW2821 Earns Orphan Drug Status from FDA for Esophageal Cancer

Fineline Cube May 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Posts pagination

1 … 387 388 389 … 688

Recent updates

  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
  • AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
  • Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
  • Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Company Medical Device

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.